NCCN Launches Funding Initiative for Advanced Breast Cancer Care
The National Comprehensive Cancer Network Oncology Research Program is excited to announce funding aimed at improving the treatment landscape for individuals living with stage four metastatic breast cancer (mBC). This essential funding initiative is designed to enhance clinical research in mBC, a condition affecting a significant number of breast cancer patients today.
Research Grants for Quality Care Improvement
Six grants have been awarded as part of this innovative program, which focuses on quality improvement projects to elevate the standard of care for patients with mBC. With the collaboration of Pfizer External Research & Grants (ER&G), this funding will support strategies that aim to optimize healthcare provider performance, thus ensuring better patient outcomes overall.
The Impact of Metastatic Breast Cancer
Statistics reveal that roughly 10% of individuals diagnosed with breast cancer present with metastatic disease right from the start. Furthermore, about 30% who initially face early-stage breast cancer will eventually develop the metastatic form. Factors influencing survival rates include tumor biology, treatment responsiveness, and access to guidelines that dictate high-quality care. The essence of this initiative is to promote better healthcare delivery and provider efficacy, ultimately leading to improved care for mBC patients.
Voices from the Leadership
“The options for treating breast cancer, particularly metastatic breast cancer, are continuously evolving,” stated Crystal S. Denlinger, MD, the Chief Executive Officer of NCCN. “We believe that everyone should be entitled to high-quality treatment, which is firmly grounded in the latest clinical evidence and expert guidelines. The researchers supported through our grants are venturing into promising areas aimed at ensuring that all patients reap the benefits of superior cancer care,” she added.
Highlighted Projects Brimming with Potential
The selected projects that received funding include a range of innovative approaches designed to tackle various challenges associated with mBC:
- Kristie Bobolis, MD, National Consortium of Breast Centers, Inc. - Focused on Certified Clinical Oncology Navigation Certification.
- Claire Conley, PhD, Georgetown University - Aiming to enhance advance care planning through quality improvement projects.
- Lucy De La Cruz, MD, Avident Health, LLC - Focusing on encouraging evidence-based shared decision-making with AI engagement tools.
- Erin Gillespie, MD, MPH, University of Washington School of Medicine - A project tailored towards optimizing practices for patients with bone metastases.
- Jamie Myers, PhD, RN, University of Kansas School of Nursing - Concentrated on enhancing treatment adherence through community support mechanisms.
- Erin Wagner, BS, After Cancer - Dedicated to developing training on sexual health in metastatic breast cancer care.
Expert Review and Longevity of Projects
All proposals underwent meticulous peer review by a Scientific Review Committee, composed of prominent oncologists from respected cancer institutions. The projects chosen are anticipated to reach their goals within two years, facilitating significant improvements in breast cancer care.
The Role of NCCN ORP in Cancer Research
The NCCN Oncology Research Program plays a pivotal role in championing innovation and advancing the understanding of cancer treatment through support for clinical trials and research initiatives. In pursuit of enhancing collaborations within cancer research, the NCCN ORP also maintains a wealth of resources that assist professionals in navigating cancer care improvements.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network (NCCN) stands out as a notable non-profit alliance dedicated to educational and research initiatives in cancer care. Over its three-decade journey, NCCN has committed itself to promoting effective and equitable healthcare through comprehensive guidelines that serve as a benchmark in oncology. The organization’s Clinical Practice Guidelines in Oncology are recognized worldwide and provide transparent, evidence-based guidance for optimal cancer treatment.
Frequently Asked Questions
What is the purpose of NCCN's funding initiative?
NCCN's funding initiative aims to advance clinical research and improve treatment delivery for patients with metastatic breast cancer.
How many grants were awarded in this initiative?
Six grants have been awarded to support quality improvement projects for metastatic breast cancer care.
Who leads the NCCN?
Crystal S. Denlinger, MD, serves as the Chief Executive Officer of NCCN.
What is metastatic breast cancer?
Metastatic breast cancer refers to breast cancer that has spread from the original tumor to other parts of the body.
How can one learn more about the NCCN's guidelines?
Detailed information about NCCN's guidelines and programs can be found on their official website.
